Quoin Pharma (QNRX) swaps $177,849 debt into director ADSs

Rhea-AI Filing Summary

Quoin Pharmaceuticals, Ltd. (QNRX) reported that director Dennis Langer acquired 34,534 ADSs on August 27, 2026 in a grant/award-type transaction. The company and Langer entered an exchange agreement under which $177,849 of accrued interest on a previously purchased note was exchanged for these ADSs at $5.15 per ADS. Following this debt-for-equity exchange, Langer directly holds 56,243 ADSs. Each ADS represents 35 ordinary shares of Quoin Pharmaceuticals.

Insider Trade Summary

Net Buyer: 34,534 shares

Net Buy 1 txn

Insider LANGER DENNIS

Role Director

Type	Security	Shares	Price	Value
Grant/Award	ADSs F1, F2	34,534	$5.15	$178K

Holdings After Transaction: ADSs — 56,243 shares (Direct)

Footnotes (2)

1. F1. Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
2. F2. On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $177,849 of accrued interest outstanding ("Outstanding Debt") owed in connection with a note previously purchased by the Reporting Person was exchanged for 34,534 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors.

Key Figures

ADSs acquired: 34,534 ADSs Transaction price per ADS: $5.15 per ADS Outstanding Debt exchanged: $177,849 +2 more

5 metrics

ADSs acquired 34,534 ADSs Grant/award acquisition on August 27, 2026

Transaction price per ADS $5.15 per ADS Price reported for the 34,534 ADSs acquired

Outstanding Debt exchanged $177,849 Accrued interest outstanding exchanged for 34,534 ADSs

ADS holdings after transaction 56,243 ADSs Direct holdings of Dennis Langer following the acquisition

ADS to ordinary share ratio 1 ADS represents 35 ordinary shares Representation of Quoin Pharmaceuticals’ ordinary shares by ADSs

Key Terms

American Depositary Shares, exchange agreement, Outstanding Debt

3 terms

American Depositary Shares financial

"Ordinary Shares are represented by American Depositary Shares ("ADSs")."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

exchange agreement financial

"the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which"

A written deal in which two parties agree to swap assets, securities or obligations under set terms—think of it as a formal swap or trade contract. For investors it matters because such agreements can change who owns what, alter a company’s capital structure, affect future cash flows or dilute existing shares, and therefore influence value and risk in a straightforward, contract-driven way.

Outstanding Debt financial

"accrued interest outstanding ("Outstanding Debt") owed in connection with a note"

FAQ

What insider transaction did QNRX director Dennis Langer report on this Form 4?

Dennis Langer reported an acquisition of 34,534 ADSs of Quoin Pharmaceuticals, Ltd. on August 27, 2026, classified as a grant, award, or other acquisition transaction.

How many QNRX ADSs does Dennis Langer own after this transaction?

After the reported transaction, Dennis Langer directly owns 56,243 ADSs of Quoin Pharmaceuticals, Ltd., as stated in the post-transaction holdings figure.

What was exchanged for the 34,534 QNRX ADSs received by Dennis Langer?

Quoin Pharmaceuticals, Ltd. and Dennis Langer entered an exchange agreement under which $177,849 of accrued interest outstanding on a note previously purchased by Langer was exchanged for 34,534 ADSs.

What price per QNRX ADS is reported in the Dennis Langer Form 4 transaction?

The Form 4 reports a transaction price of $5.15 per ADS for the 34,534 ADSs acquired by Dennis Langer in the August 27, 2026 exchange.

How do QNRX ADSs relate to ordinary shares in this filing?

The filing states that Quoin Pharmaceuticals’ ordinary shares are represented by American Depositary Shares (ADSs), and that each ADS represents thirty-five (35) ordinary shares of the issuer.

Was the QNRX debt-for-equity exchange with Dennis Langer approved by governance bodies?

Yes. The filing states that the exchange agreement and the exchange of $177,849 Outstanding Debt for 34,534 ADSs were approved in advance by Quoin Pharmaceuticals’ audit committee and board of directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 06:41 PM Accepted by SEC EDGAR 08/28/2026 - 06:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LANGER DENNIS

(Last) (First) (Middle)

C/O QUOIN PHARMACEUTICALS LTD.,

42127 PLEASANT FOREST COURT

(Street)

ASHBURN VIRGINIA 20148

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ADSs(1)	08/27/2026		A(2)		34,534	A	$5.15	56,243	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.

2. On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $177,849 of accrued interest outstanding ("Outstanding Debt") owed in connection with a note previously purchased by the Reporting Person was exchanged for 34,534 ADSs. The exchange agreement and the exchange of the Outstanding Debt for the ADSs was approved in advance by the Issuer's audit committee and board of directors.

	/s/ Dennis Langer	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)